Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Overview
Date Founded

1988

Headquarters

777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591

Type of Company

Public

Employees (Worldwide)

8,100

Industries

Pharmaceuticals
Biotechnology

Company Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Contact Data
Trying to get in touch with decision makers at Regeneron Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder, President & Chief Executive Officer

Chief Financial Officer & Executive Vice President-Finance

Secretary, Executive Vice President & General Counsel

Associate General Counsel & Chief Compliance Officer

Chief Accounting Officer, Vice President & Controller

Executive Vice President & General Manager, Industrial Operations & Product Supply

Senior Vice President & Head of Commercial

Senior Vice President, Immuno-Oncology & Head of Bispecifics

Vice President, Head, Regeneron Genetics Center

Board of Directors

Former President & Chief Executive Officer at Merck & Co., Inc.

Co-Founder at Regeneron Pharmaceuticals, Inc.

Co-Founder, President & Chief Executive Officer at Regeneron Pharmaceuticals, Inc.

President at Stanford University

Former Founder & Director at Peloton Therapeutics, Inc.

Professor & Chairman-Molecular Genetics Department at The University of Texas - Southwestern Medical Center

Chairman-Molecular Biology Department & Professor at Princeton University

Senior Advisor, Healthcare Banking at Barclays Plc

Chairman at Prudential Fixed Income

Director, Jan & Dan Duncan Neurological Research Institute at Texas Children's Hospital

Paths to Regeneron Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Regeneron Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

In 1951, marking the 25th anniversary of the founding of Loomis, Sayles & Company, Robert H. Loomis sent a clear message to all clients. Click here to read. More than 60 years later, I echo the words of our founder when he said, "we wish to express our gratitude and appreciation to those who, through these difficult years, have helped us to the success we have enjoyed. We look to the future with humility but with confidence." The biggest difference in today's world is that our pace is faster and our playing field is larger. Given this scenario, our job at Loomis Sayles is to keep a laser-like “eye on the ball” particularly during times of uncertainty and volatility, where both risk and opportunity reside. My goal is to ensure that Loomis Sayles remains a broad-based, house of excellence trusted by our clients and recognized for our record of: Attracting and retaining exceptional investment professionals Providing caring, highly ethical and informative services to our clients Producing strong investment performance across our full stable of products The last five years have been a time of tremendous innovation for us. We have grabbed hold of opportunities presented by market upheaval to unearth some tremendous investments, build off our base and empower people to construct and test new capabilities. By integrating these with existing capabilities, (quantitative research, deeper risk analysis, greater macro-economic firepower, absolute return-oriented strategies and securitized capabilities), I believe we are a better investment firm than ever. On behalf of all Loomis Sayles employees, thank you for placing your confidence in us. From my personal vantage point, I am more confident than ever about the future of our company and the skills and passion of our people to deliver excellence in their work. We look forward to serving your investment needs as we face the ever-changing future together.

Details Hidden

Renaissance Technologies LLC is an investment management company dedicated to producing superior returns for its clients and employees by adhering to mathematical and statistical methods.

Details Hidden

Polen Capital employs a disciplined, bottom-up, concentrated US, Global and International equity investment strategies that focus on high quality growth investments. The Polen Focus Growth strategy invests in a concentrated portfolio of primarily large-cap US common stocks with sustainable competitive advantages. The Polen Global Growth strategy invests in a concentrated portfolio of outstanding US and international businesses with competitive advantages and the potential for sustained superior growth. It emphasizes sustainable earnings growth and focuses on companies with high returns on capital and double digit earnings growth. The Polen International Growth strategy applies the same philosophy as the Focus Growth and Global Growth portfolios, but invests exclusively in businesses domiciled outside of the US.

Recent Transactions
Details Hidden

Regeneron Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Regeneron Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Regeneron Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Underwriter

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Auditor

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onRegeneron Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Skadden, Arps, Slate, Meagher & Flom LLP

Advisor

Dean, Translational Biomedical Sciences at Icahn School of Medicine at Mount Sinai

Advisor

Executive Managing Director, Project Management at Colliers International NY LLC

Clients

Cigna Corp. is a global health service company, which is dedicated to improving the health, well-being and peace of mind. Its products and services include an integrated suite of health services such as medical, dental, behavioral health, pharmacy, vision, supplemental benefits and other related products including group life, accident and disability insurance.

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Key Stats and Financials As of 2019
Market Capitalization
$54B
Total Enterprise Value
$40.5B
Earnings Per Share
$18.46
Revenue
$7.86B
Net Profit
$2.12B
Total Debt
$714M
Total Equity
$11.1B
Five Year Compounded Annual Growth Rate Of Revenue
22.77%
Three Year Compounded Annual Growth Rate Of Revenue
17.39%
Debt TEV
0.02x
TEVNet Income
19.16x
Enterprise Value EBITDAOperating
16.75x
Enterprise Value / Sales
5.15x
EBITDAMargin
30.78%
EBITDA
$2.42B
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
$475K
2010
Investments
Details Hidden

DNAnexus, Inc. develops a cloud-based data analysis and management platform for DNA sequence data. It engages in the provision of cloud-based solutions for large-scale Deoxyribonucleic acid (DNA) data management and analysis. The firm offers a centralized hub for managing data, collaborating with other scientists, sharing tools, and accessing diverse reference datasets, including genotypic and phenotypic data. The company was founded by Serafim Batzoglou, Andreas Sundquist and Arend Sidow in 2009 and is headquartered in Mountain View, CA.

Details Hidden

Vyriad, Inc. manufactures pharmaceutical products for cancer. Its technology include pipeline, non-invasive imaging, and oncolytic vaccine development. The company was founded by Stephen J. Russell, Glen Barber, Shruthi Naik, Kah Whye Peng, and Mark Federspiel in 2016 and is headquartered in Rochester, MN.

Details Hidden

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Suppliers
Intellia Therapeutics, Inc. Medical Support Services | Cambridge, MA

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Adverum Biotechnologies, Inc. Pharmaceuticals | Redwood City, CA

Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

Adicet Therapeutics, Inc. Pharmaceuticals | Beverly Hills, CA

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

GlaxoSmithKline Plc Pharmaceuticals - Brentford, Gbr

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Awards & Honors
Rank #85
2017
Fortune Magazine - The 100 Best Companies to Work For
Sponsored by Fortune Magazine
Rank #583
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #5
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Regeneron Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Regeneron Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Regeneron Pharmaceuticals, Inc..